TB-500 FDA Approval History: Regulatory Status, Compounding Rules, and Safety Profile

TB-500 Has Never Been FDA Approved

TB-500 holds no FDA approval, and no sponsor has submitted a New Drug Application (NDA) or Biologics License Application (BLA) for this peptide. The Drugs@FDA database returns zero results for "thymosin beta-4," "TB-500," or "TB-4." That absence is not a technicality. It means no sponsor has completed the preclinical toxicology, Phase I/II/III clinical trial sequence, and Chemistry, Manufacturing, and Controls (CMC) package the FDA requires before granting market authorization.

The parent molecule, thymosin beta-4, was first isolated from calf thymus in 1981 by Allan Goldstein's laboratory at George Washington University. Decades of basic-science publications documented its roles in actin sequestration, wound repair, and anti-inflammatory signaling 1. Despite promising preclinical signals, no pharmaceutical company has carried a Tβ4-based drug through to approval. RegeneRx Biopharmaceuticals sponsored the furthest-advanced clinical programs (RGN-259 ophthalmic solution for dry eye and neurotrophic keratitis), but those programs used the full-length Tβ4 protein, not the TB-500 fragment, and neither reached Phase III completion 2.

TB-500 therefore exists in a gray zone. Patients can obtain it. Physicians can prescribe it. But no federal agency has evaluated its efficacy or safety through the standard drug approval process.

What TB-500 Actually Is: Molecular Identity and Nomenclature

TB-500 is a synthetic peptide corresponding to the biologically active region of thymosin beta-4. The core sequence centers on residues 17 through 23 (Ac-LKKTETQ), which research published in the Annals of the New York Academy of Sciences identified as responsible for Tβ4's actin-binding and cell-migration properties [1]. The full TB-500 product sold by compounding pharmacies typically contains a longer fragment (often 43 or 44 amino acids matching the complete Tβ4 sequence), though labeling varies by compounder.

This naming inconsistency matters for regulatory purposes. "TB-500" is not a USAN (United States Adopted Name) or an INN (International Nonproprietary Name). The FDA's Substance Registration System assigns thymosin beta-4 the UNII code 549LM7U24W, but "TB-500" appears nowhere in official nomenclature. That gap complicates pharmacovigilance: adverse events may be filed under different names, fragmenting the safety signal.

The 503A Compounding Pathway: How TB-500 Reaches Patients

Without an approved NDA, TB-500 enters U.S. commerce through Section 503A of the Federal Food, Drug, and Cosmetic Act. This section permits licensed pharmacies to compound patient-specific preparations when a licensed prescriber writes an individualized prescription. The FDA's compounding policy page outlines the requirements: 503A pharmacies must compound in response to a valid prescription, use bulk drug substances that meet USP or NF monograph standards (or appear on the FDA's positive list), and refrain from essentially copying a commercially available product.

TB-500 compounds present a specific regulatory wrinkle. Thymosin beta-4 does not appear in the USP, and the FDA has not finalized its inclusion on the 503B Bulks list. For 503A pharmacies, the requirement is less restrictive: the bulk substance must be a component of an FDA-approved drug or appear on a separate positive list, or the pharmacy must demonstrate it meets compendial standards. Because thymosin beta-4 has no approved-drug anchor, compounders typically rely on certificates of analysis from peptide synthesis suppliers, a practice the FDA has questioned in warning letters.

Between 2019 and 2024, the FDA issued at least four warning letters to compounding pharmacies citing peptide products (including thymosin-based preparations) for current Good Manufacturing Practice (cGMP) violations 3. Common findings included inadequate potency testing, missing sterility assurance documentation, and labeling that implied FDA approval where none existed.

A 503A compound is not an "approved drug prescribed off-label." It is an unapproved product made legal under narrow statutory conditions. Patients and prescribers should understand that distinction clearly.

FDA Enforcement Actions and Regulatory Scrutiny

The FDA has not issued a blanket ban on TB-500 compounding, but its enforcement posture has tightened. Several actions illustrate the trend.

In November 2019, the FDA published a revised draft guidance on bulk drug substances for 503B outsourcing facilities, listing categories of substances under evaluation. Thymosin alpha-1 (a related but distinct thymic peptide) appeared on the "difficult to evaluate" list. Thymosin beta-4 was not explicitly listed in either the positive or negative category, leaving its status unresolved for outsourcing facilities 4.

In 2020 and 2021, the FDA's FAERS database recorded a small number of adverse event reports mentioning thymosin beta-4, primarily injection-site reactions and headache. The absolute count remained low (fewer than 50 total reports through Q4 2024), though underreporting is a well-documented limitation of passive surveillance systems. A 2017 analysis in JAMA Internal Medicine estimated that FAERS captures only 1 to 10% of actual adverse drug events for marketed products; capture rates for compounded peptides may be even lower [5].

The practical takeaway: the FDA knows TB-500 is being compounded and sold. It has not moved to ban it outright, but it has signaled through warning letters and guidance documents that it views peptide compounding with heightened scrutiny.

Clinical Evidence: What Exists and What Does Not

The evidence base for TB-500 in humans is thin. No randomized controlled trial of TB-500 (the fragment product) has been published in a peer-reviewed journal as of May 2026. The clinical data that do exist involve the full-length thymosin beta-4 molecule.

Goldstein et al. (2012) published a comprehensive review of Tβ4 biology in the Annals of the New York Academy of Sciences, summarizing preclinical evidence for wound healing, cardiac repair after myocardial infarction, and neuronal protection [1]. In animal models, Tβ4 reduced infarct size by 40 to 50% when administered within 24 hours of coronary artery ligation. Those rodent data have not translated into human efficacy trials for TB-500.

RegeneRx conducted Phase II trials of RGN-259 (full-length Tβ4 in ophthalmic solution) for dry eye disease. A 2019 trial (NCT02974907) showed improvements in corneal fluorescein staining compared to placebo, but the company reported mixed primary-endpoint results and did not advance to Phase III [2]. A separate Phase II trial for neurotrophic keratitis (NCT03491956) showed more promising corneal healing rates, but this program also stalled before key trials.

For the musculoskeletal and recovery indications that drive most consumer interest in TB-500, the evidence consists entirely of preclinical studies and case series. A 2016 paper in the Journal of Orthopaedic Research demonstrated that Tβ4 accelerated tendon healing in a rat Achilles model, with treated tendons showing 30% greater tensile strength at 14 days versus controls [6]. Extrapolating those doses and outcomes to humans requires assumptions the data cannot support.

"The gap between the preclinical promise of thymosin beta-4 and its clinical validation remains wide," wrote Dr. Hynda Kleinman of the National Institutes of Health in a 2014 review in Expert Opinion on Biological Therapy [7]. That assessment has not materially changed in the years since.

The TB-500 Label Problem

TB-500 has no FDA-approved label. Period. Any "label" a patient sees on a TB-500 vial is pharmacy-generated, reflecting the compounder's formulation decisions rather than FDA-reviewed prescribing information. This distinction has direct clinical consequences.

An approved drug label includes specific sections mandated by 21 CFR 201.57: indications, dosage and administration, contraindications, warnings and precautions, adverse reactions, drug interactions, and use in specific populations. A compounded TB-500 vial typically carries only the drug name, concentration (often 5 mg per vial for lyophilized powder), lot number, beyond-use date, and pharmacy contact information.

Without standardized labeling, dosing varies widely in practice. Online prescribing protocols range from 2.5 mg twice weekly to 10 mg weekly, with injection routes including subcutaneous and intramuscular. No dose-ranging study has established an optimal human dose. The Endocrine Society's 2020 position statement on compounded hormones and peptides warned that compounded peptides lacking standardized labeling expose patients to dosing errors and undetected drug interactions [8].

International Regulatory Status

TB-500 occupies a similar regulatory void outside the United States. The European Medicines Agency (EMA) has not evaluated any Tβ4 or TB-500 product through the centralized marketing authorization procedure. No EPAR (European Public Assessment Report) exists for this molecule.

In Australia, the Therapeutic Goods Administration (TGA) classifies thymosin beta-4 as a Schedule 4 (prescription-only) substance. Australian compounding rules differ from U.S. 503A provisions; however, the practical result is similar. Patients access TB-500 through compounding pharmacies with a valid prescription, and no TGA-evaluated product exists 9.

The World Anti-Doping Agency (WADA) added thymosin beta-4 to its Prohibited List in 2010 under category S2 (peptide hormones, growth factors, related substances, and mimetics). Multiple athletes have received sanctions for TB-500 use, including several high-profile cases in Australian Rules football between 2013 and 2015 10. WADA's prohibition reflects concern about performance-enhancing potential, not a safety determination, but it signals that TB-500 is on international regulators' radar.

Safety Profile: Known Risks and Evidence Gaps

The safety profile of TB-500 in humans is largely unknown in the formal pharmacovigilance sense. No sponsor has compiled the standardized safety datasets (Integrated Summary of Safety, periodic safety update reports) that accompany an approved drug.

From the available preclinical and early clinical data on full-length Tβ4, the most commonly reported adverse effects were mild: injection-site erythema, transient headache, and fatigue 1. The RegeneRx Phase II dry-eye trials reported no serious adverse events in Tβ4-treated arms 2.

A theoretical concern surrounds Tβ4's role in angiogenesis and cell migration. Because these pathways overlap with tumor biology, oncologists have raised questions about whether exogenous Tβ4 could promote cancer growth. A 2014 study in Cancer Research found elevated Tβ4 expression in colorectal cancer tissue versus normal mucosa, suggesting a role in tumor progression [11]. Whether administering exogenous TB-500 at therapeutic doses replicates this risk is unknown. No epidemiological study has linked TB-500 use to increased cancer incidence, but no study has been powered to detect such a signal either.

Contamination risk represents a separate safety axis. Compounded peptides depend on the quality of the bulk active pharmaceutical ingredient and the sterility of the compounding process. A 2012 multistate fungal meningitis outbreak traced to contaminated compounded methylprednisolone (not TB-500) killed 64 people and prompted Congress to pass the Drug Quality and Security Act of 2013, which created the 503B outsourcing facility framework 12. That tragedy underscored the stakes of compounding without the cGMP infrastructure required for approved drugs.

Patients using compounded TB-500 should verify that their pharmacy holds state board accreditation, undergoes third-party sterility testing, and provides certificates of analysis for each batch.

What Would FDA Approval Require?

For TB-500 to move from compounded peptide to approved drug, a sponsor would need to complete the full IND-to-NDA pipeline (or BLA pipeline, depending on whether the FDA classifies TB-500 as a drug or biologic). The Biologics Price Competition and Innovation Act of 2009 established that proteins produced by recombinant DNA technology are regulated as biologics, but synthetic peptides of fewer than 40 amino acids may qualify as drugs under CDER jurisdiction.

The required steps would include: formal IND submission with preclinical toxicology, Phase I safety and pharmacokinetic studies in 20 to 80 subjects, Phase II dose-ranging trials in the target indication (likely 100 to 300 subjects), and Phase III confirmatory trials (typically 500 to 3,000 subjects). The entire process takes a median of 10 to 15 years and costs an estimated $1.3 billion per Tufts Center for the Study of Drug Development estimates [13].

No company has publicly announced plans to file an IND for TB-500 as of May 2026. Without patent protection on the peptide itself (thymosin beta-4's sequence has been public since 1981), the commercial incentive to invest $1 billion-plus in clinical development is minimal. This economic reality, not a safety ban, explains why TB-500 remains unapproved.